Haemonetics (HAE) Misses Q2 EPS by 1c, Lowers FY EPS Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall St tumbles on tech selloff as concerns about hawkish Fed, AI spending mount
- SpaceX extends losses after $600 billion wipeout, tech stocks slide again
- Oil steady as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Haemonetics (HAE) PT Lowered to $80 at Jefferies
November 10, 2021 8:10 AM ESTJefferies analyst Anthony Petrone lowered the price target on Haemonetics (NYSE: HAE) to $80.00 (from $85.00) while maintaining a Buy rating.
The analyst commented, "Key updates from the call: 1) US plasma volumes improved to +20% (+14% last Q), 2) Nov volumes flat at +20% (high-end of revised... More
